Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events

Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events

Abstract Background Immune checkpoint inhibiting antibodies were introduced into routine clinical practice for cancer patients. Checkpoint blockade has led to durable remissions in some patients, but may also induce immune-related adverse events (irAEs). Lung cancer patients show an increased risk f...

Full description

Bibliographic Details
Main Authors: Heinz Läubli, Catharina Balmelli, Lukas Kaufmann, Michal Stanczak, Mohammedyaseen Syedbasha, Dominik Vogt, Astrid Hertig, Beat Müller, Oliver Gautschi, Frank Stenner, Alfred Zippelius, Adrian Egli, Sacha I. Rothschild
Format: Article
Language:English
Published: BMJ Publishing Group 2018-05-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Cancer immunotherapy
Immune-related adverse events (irAE)
Checkpoint inhibitor
Vaccine response
Influenza vaccine
Online Access:http://link.springer.com/article/10.1186/s40425-018-0353-7

Internet

http://link.springer.com/article/10.1186/s40425-018-0353-7

Similar Items